EP300 and metastatic melanoma: As seen with 5-year survival, loss of nuclear p300 was associated with poor overall and disease-specific 10-year survival in all melanoma (Figure 4A, B), primary melanoma (Figure 4C, D), as well as metastatic melanoma patients (Figure 4E, F).